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Abstract 
Background: Lyn, an import member of Src family kinases (SFKs), is supposed to be implicated in acute myeloid 
leukemia (AML) pathogenesis and development by participation in AML differentiation, yet the details still remain 
incompletely understood. The expression status of Lyn and its correlation with multiple clinical parameters including 
cell differentiation degree, different cytogenetic risk classification, and the activity of myeloperoxidase (MPO) were 
thus investigated. To address the mechanisms underlying the involvement of Lyn in differentiation induction, the 
effects of dasatinib, an inhibitor for SFKs including Lyn, on the alterations of all-trans retinoic acid (ATRA)- or dihydroxy-
vitamin D3 (VD3)-induced differentiation, and c-Myc protein expression were investigated.
Methods: Primary AML blasts were obtained from 31 newly diagnosed AML patients with different French-Ameri-
can-British (FAB) subtypes. The expression of phosphorylated and total Lyn, c-Myc, and CD11b, CD11c and CD15 was 
analyzed by flow cytometry. The activation of Akt and Erk known to be involved in the regulation of c-Myc expression 
was investigated using western blotting.
Results: Significant higher expression levels of total Lyn were observed in AML patients with favorable cytogenetics, 
higher MPO activity and FAB M2 subtype. A clear positive correlation between the expression levels of Lyn and dif-
ferentiation status of primary AML blasts was observed. Dasatinib inhibited the expression of phosphorylated Lyn, and 
further enhanced the differentiation-inducing activity of ATRA and VD3 in HL-60 cells. Augmented downregulation 
of c-Myc protein expression was observed in the combination treatment with ATRA, VD3 and dasatinib compared to 
treatment with each reagent alone in HL-60 cells. The suppression of the activation of Akt and Erk was also observed 
concomitantly.
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Background
Acute myeloid leukemia (AML) is one of the major 
hematologic neoplasms, and is characterized by defec-
tive differentiation and excessive accumulation of prolif-
erative progenitor cells in the bone marrow and blood. 
AML has several subtypes and its treatment and prog-
nosis varies among subtypes. Although conventional 
and/or advanced treatment strategy employing all-trans 
retinoic acid (ATRA) in combination with other drugs 
including arsenic trioxide has dramatically improved the 
prognosis for acute promyelocytic leukemia (APL) [1–3], 
unfavorable outcomes due to the relapse and drug resist-
ance are still a serious concern in other subtype of AML 
with five-year disease-free survival rates of less than 50 % 
[4–6]. Because of the lack of effective molecular-target-
ing agents, the treatment strategy for non-APL AML is 
limited to chemotherapy with or without hematopoietic 
stem cell transplantation to date.
Src family kinases (SFKs) are a unique group of 
enzymes that have critical roles in cell proliferation, sur-
vival, differentiation, adhesion and migration in leuke-
mias and solid tumors, as well as in embryonic stem cell 
development [7–9]. Pharmacologic inhibition of SFKs 
by their inhibitors, such as PP2 or dasatinib, inhibits the 
growth of human leukemia cell lines and primary AML 
blast cells [10, 11]. Lyn, an important SFK family mem-
ber, expressed in an active form in AML cells and is sup-
posed to play a critical role in AML differentiation and 
known to be responsible for imatinib-resistant leukemias 
[10, 12, 13]. Especially, dasatinib has proven success-
ful in the treatment of imatinib-resistant leukemias in 
which the effects of dasatinib are likely attributed to the 
inhibition of Lyn [12, 14–16]. Although these previous 
findings strongly implicate Lyn in AML pathogenesis or 
disease development, the detailed systematic analysis of 
the expression status of Lyn in different subtypes of AML 
has not yet been preformed.
HL-60 cells are known as a good model for leukemo-
genesis research and differentiation study in  vitro [17, 
18]. Interestingly, Lyn has been demonstrated to be the 
predominant activated SFK in HL-60 cells, although 
other SFK members such as Lck, Fyn, Hck also expressed 
in the cells [12]. However, the detailed investigation 
focused on the involvement of Lyn in the induction of 
differentiation in HL-60 cells by different stimulants has 
not yet been sufficiently conducted.
The c-Myc transcription factor is a potent regulator of 
a variety of cell activities such as proliferation and differ-
entiation [19]. Deregulated c-Myc expression is common 
in the highly proliferative leukemias and lymphomas 
which are blocked at an earlier stage of differentiation 
[20–22]. In fact, repression of c-Myc has been reported 
to be required for terminal differentiation of malignant 
hematopoietic cells including HL-60 cells induced by dif-
ferent stimulants such as ATRA and dihydroxyvitamin 
D3 (VD3) [23–26]. However, details of the correlation 
between c-Myc and Lyn still remain incompletely under-
stood in view of their roles in differentiation induction.
In this study, based on our hypothesis that Lyn expres-
sion may differ in individual patients and could be related 
with some clinical parameters due to the heterogeneity of 
AML, the expression status of total and phosphorylated 
Lyn in primary AML cells from patients with different 
subtypes of AML were first investigated. The correla-
tion between Lyn expression status and multiple clinical 
parameters including cell differentiation degree, different 
cytogenetic risk classification, and the activity of mye-
loperoxidase (MPO) were further evaluated. In order to 
address the mechanisms underlying the involvement of 
Lyn in differentiation induction, the effects of dasatinib, 
an inhibitor for SFKs including Lyn, on the alterations of 
ATRA- or VD3-induced differentiation, the expression of 
c-Myc in HL-60 cells were further investigated. Since Akt 
and Erk have been demonstrated to be involved in com-
plex signaling pathways responsible for the regulation of 
c-Myc expression [19, 27–29], the activation of Akt and 
Erk was further investigated.
Methods
Cell line and materials
HL-60, a human non-APL AML cell line, was obtained 
from the Health Science Research Resources Bank 
(Tokyo, Japan). ATRA and VD3 were purchased from 
Sigma (St. Louis, MO, USA) and dissolved in ethanol 
to obtain a final concentration of 1  mM and 100  μM, 
respectively, and stored at −20 °C in the dark. Dasatinib 
Conclusions: The expression level of total Lyn is closely linked to the differentiation status of AML blasts. The 
enhancement of differentiation-inducing activity of ATRA/VD3 by dasatinib suggested that Lyn was associated in the 
negative regulation of ATRA/VD3-induced HL-60 cells differentiation. The enhancement probably was attributed to 
the downregulation of c-Myc implicated with the suppression of the activation of Akt and Erk. These results provide 
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possibilities for the combination therapy with VD3 and dasatinib.
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was purchased from BioVision (Mountain View, CA, 
USA) and dissolved in dimethyl sulfoxide (DMSO) at a 
concentration of 1  mM. Phycoerythrin (PE)-conjugated 
mouse anti-human CD11b IgG, fluorescein isothiocy-
anate (FITC)-labeled mouse anti-human CD11c IgG, 
and the PE and FITC-conjugated isotype control IgG 
were obtained from Becton–Dickinson (San Jose, CA, 
USA). FITC-labeled polyclonal antibodies for total and 
phosphorylated Lyn (Y396) were purchased from Bioss 
(Woburn, MA, USA). Rabbit anti-human c-Myc poly-
clonal antibody and its negative control (non-binding 
rabbit IgG) were purchased from GeneTex (Irvine, CA, 
USA). FITC-labeled goat anti-rabbit polyclonal IgG anti-
body (secondary antibody) was purchased from Jackson 
ImmunoResearch (West Grove, PA, USA).
Preparation of primary AML blasts
Primary AML blasts were obtained from 31 newly diag-
nosed AML patients with different French-American-
British (FAB) subtypes, except for FAB M3 (APL). Prior 
to clinical therapy, mononuclear cell fractions were iso-
lated from freshly collected bone marrow aspirates or 
peripheral blood using Lymphoprep™ (Cosmo Bio Co., 
Ltd., Tokyo, Japan), and the cell fractions were then cryo-
preserved in liquid nitrogen until use. Prior to conducting 
the experiments, aliquots of the AML cells were rapidly 
thawed at 37  °C and washed with PBS. Cells were then 
stained with Wright-Giemsa solution to confirm blastoid 
cell content and more than 90 % of blastoid cell fraction 
was ensured in all samples. The study was approved by 
the Internal Review Committee of Nihon University Ita-
bashi Hospital.
Cell culture and treatment
HL-60 cells were maintained in RPMI 1640 medium 
(Sigma) supplemented with 10  % heat-inactivated fetal 
bovine serum (FBS) (Gibco BRL, Grand Island, NY, USA), 
100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco 
BRL) at 37  °C in a humidified atmosphere (5  % CO2 in 
air). Cells were seeded at a density of 1 × 105 cells/ml and 
treated with 1 μM ATRA, 100 nM VD3, 300 nM dasat-
inib, alone or in combination, for the indicated time. 
Dose titration study revealed that less than or equal to 
1 μM of dasatinib had no apoptotic effect on HL-60 cells 
(data not shown). Hence, we applied 300 nM of concen-
tration as shown previously [14].
Differentiation analysis
Differentiation induction was confirmed by morphology 
and expression of surface markers CD11b and CD11c. 
For morphological assessment, cytospin preparations 
of treated cells stained with Wright-Giemsa were evalu-
ated by light microscopy as previously described [30, 31]. 
Myeloid maturation with cell surface marker was ana-
lyzed by flow cytometry (FACSCalibur, Becton–Dickin-
son, Franklin Lakes, NJ), as described previously [31, 32]. 
In brief, approximately 1 ×  106 cells were washed with 
phosphate-buffered saline (PBS) containing 2.5  % FBS 
and 0.5 % NaN3 (PBSF) and stained with anti-CD11b and 
CD11c antibodies for 30  min at 4  °C in the dark. Cells 
were then washed three times with PBSF and analyzed 
by flow cytometry with a minimum acquisition of 10,000 
events for HL-60 and 5000 events for primary AML cells 
prepared from patients, respectively. Non-binding mouse 
PE and FITC-labeled IgG was used as control. Assess-
ment of the expression of CD15 by flow cytometry was 
entrusted to Bio Medical Laboratories, Inc. (BML, Inc., 
Tokyo, Japan).
Detection of the expression of total, phosphorylated Lyn 
and c‑Myc
Cells were harvested and washed once with PBS, and 
further fixed with 4  % formaldehyde/PBS at 37  °C for 
10 min. After permeabilization with 90 % ice-cold metha-
nol at −20 °C over 2 h, cells were washed once with PBSF 
and stained with anti-total, phosphorylated Lyn, and 
c-Myc antibody, respectively. FITC-labeled anti-rabbit 
secondary antibody was used for the detection of c-Myc. 
The expression levels of total and phosphorylated Lyn 
in primary AML cells were analyzed by flow cytometer 
(Cyto ACE-150, Jasco, Tokyo, Japan), and the results were 
shown as mean fluorescence intensity (MFI) with linear 
scaling and calculated by subtracting the mean fluores-
cence of the unstained cells from that of the stained cells, 
as described previously [30, 32–34]. Similarly, the expres-
sion levels of phosphorylated Lyn in HL-60 cells were 
also analyzed by flow cytometry (FACSCalibur) and were 
shown as MFI. The expression levels of c-Myc were eval-
uated using flow cytometer (Cyto ACE-150) and were 
shown as positive rates.
Western blot
Protein samples were separated on an SDS-PAGE, fol-
lowed by transferring to a nitrocellulose membrane as 
described previously [30]. Protein bands were detected 
using the following primary antibodies: mouse anti-
human β-actin (1:5000 dilution, Sigma-Aldrich); rabbit 
anti-human phospho-p44/42 MAPK (Erk1/2) (Thr202/
Tyr204) (1:2000 dilution) and p44/42 MAPK (Erk1/2) 
(1:1000 dilution); rabbit anti-human phospho-Akt 
(Ser473) (1:2000 dilution) and Akt (1:1000 dilution) 
(Cell Signaling Technology, MA, USA). Blotted protein 
bands were detected with respective horseradish perox-
idase-conjugated secondary antibody and an enhanced 
chemiluminescence (ECL) western blot analysis system 
(Amersham Pharmacia Biotech, Buckinghamshire, UK).
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Statistical analysis
Experiments were independently repeated more than 
three times and results are shown as mean ±  standard 
deviation (SD). A two-tailed paired t test was used to 
assess the difference between two groups. The correla-
tion in two factors was evaluated with Pearson product-
moment correlation coefficient. A p value less than 0.05 
was considered to be significant.
Results
Correlation between Lyn expression level and clinical 
laboratory parameters
Lyn has been demonstrated to be the major SFK family 
member expressed in an active form in AML cells [10, 
12], the expression levels of Lyn in primary AML cells 
from 31 patients with different subtypes of AML were 
thus investigated and summarized in Table  1. Multiple 
clinical parameters of individual patients enrolled into 
the study were also shown in Table  1. Flow cytometry 
data for representative samples with high or low Lyn 
expression level were shown in Fig.  1a. The expression 
levels of phosphorylated Lyn in 20 samples of the 31 pri-
mary AML blasts were further evaluated. A strong posi-
tive correlation between the expression levels of total and 
phosphorylated Lyn was observed (Fig.  1b), suggesting 
its biological and clinical significance in AML pathogen-
esis and development. Intriguingly, significant higher 
expression levels of Lyn were observed in AML patients 
with favorable cytogenetics compared to intermediate or 
poor cytogenetic risk group according to MRC10 crite-
ria [35] (Fig. 2a; Table 1). Much higher expression levels 
of Lyn were observed in patients with FAB M2 subtype 
compared to all other FAB subtypes, and a significant 
difference in its expression level was further confirmed 
between patients with FAB M2 and FAB M0/M1 (Fig. 2b; 
Table 1). Significant higher expression levels of Lyn were 
also observed in patients with higher myeloperoxidase 
(MPO) activity (more than 50  % MPO-positive blasts), 
known to be closely associated with cell differentiation 
status (Fig.  2c; Table  1). Consistent with this, a positive 
correlation was observed between the expression levels 
of Lyn and CD15, a major myeloid maturation marker 
(Fig. 2d). Interestingly, there was a strong inverse corre-
lation between the expression levels of Lyn and patients’ 
age (Fig.  2e), whereas, no correlation was observed 
between its expression and the white blood cell (WBC) 
numbers of patients (Fig. 2f ).
Inhibition of phosphorylation of Lyn and enhancement 
of differentiation‑inducing activity of both ATRA and VD3 
by dasatinib in HL‑60 cells
Lyn plays a critical role in AML differentiation, and is 
the predominant activated SFK in AML cells such as 
HL-60 [10, 12]. Flow cytometric analysis was thus first 
performed to confirm the expression status of phospho-
rylated Lyn and clarify the effect of dasatinib, an inhibi-
tor for SFKs including Lyn, on its expression level in 
HL-60 cells after treatment with 300  nM dasatinib for 
30  min. Consistent with previous reports [10, 12], the 
expression of phosphorylated Lyn was confirmed, and 
an apparent inhibitory effect of dasatinib on its expres-
sion was observed (Fig.  3a). To determine the effects of 
dasatinib on ATRA- or VD3-induced differentiation, 
HL-60 cells were treated with 1  μM ATRA or 100  nM 
VD3 in the presence of absence of 300 nM dasatinib for 
72 h, followed by morphological analysis and flow cyto-
metric analysis of the myeloid differentiation markers 
CD11b and CD11c (Fig. 3b–d). HL-60 cells treated with 
ATRA or VD3 alone underwent apparent differentiation-
associated changes with condensation and lobulation of 
nuclei (Fig. 3b), accompanied by a significant increase in 
the expression levels of CD11b and/or CD11c (Fig.  3c, 
d). Furthermore, the number of cells containing multi-
lobulated nuclei prominently increased when cells were 
treated with ATRA or VD3 in combination with dasat-
inib compared to when treated with ATRA or VD3 alone 
(Fig.  3b). The enhancement in differentiation-inducing 
activity due to the combination treatment was further 
confirmed by a significant increase in the expression lev-
els of CD11b and CD11c (Fig. 3c, d). Moreover, in com-
parison to control groups, no morphological change and 
alteration in the expression levels of the two differen-
tiation markers was observed when treated by dasatinib 
alone (Fig. 3b–d).
Potentiation of ATRA‑ or VD3‑induced c‑Myc 
downregulation by dasatinib in HL‑60 cells
Since deregulated c-Myc expression is common in the 
highly proliferative leukemias and lymphomas which are 
blocked at an earlier stage of differentiation [20–22], the 
alteration of c-Myc expression in HL-60 cells was exam-
ined by intracytoplasmic staining using flow cytometry 
after treatment with 1  μM ATRA and 100  nM VD3, 
each alone or in combination with 300  nM dasatinib 
for 72 h. As shown in Fig. 4, ATRA, VD3 and dasatinib 
alone induced slightly but significantly downregulation 
of c-Myc expression. Furthermore, dasatinib signifi-
cantly potentiated the capacity of both ATRA and VD3 to 
downregulate the expression level of c-Myc.
Expression profiles of phosphorylated and total Akt 
and Erk in HL‑60 cells treated with ATRA and VD3, each 
alone or in combination with dasatinib
After treatment with 1 μM ATRA and 100 nM VD3, each 
alone or in combination with 300 nM dasatinib for 24 h, the 
alterations of the expression levels of phosphorylated and 
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total Akt and Erk proteins were evaluated by western blot-
ting. As shown in Fig. 5, the expression levels of phosphoryl-
ated form of each protein were prominently downregulated 
by ATRA and VD3, respectively, whereas almost no altera-
tion was observed in their total form. Intriguingly, dasatinib 
per se did not affect the expression levels of phosphorylated 
form of each protein as compared to control group, and also 
showed no influence on ATRA- or VD3-triggered downreg-
ulation of respective protein expression level.
Discussion
In this study, we first demonstrated that significant higher 
expression levels of total Lyn were observed in AML 
patients with favorable cytogenetics, higher MPO activity 
and FAB M2 subtype, which is also known as myeloblastic 
leukemia with maturation (Figs. 1, 2a–c; Table 1). Further-
more, a clear positive correlation was observed between the 
expression levels of Lyn and CD15 (Fig. 2d), suggesting for 
the first time that Lyn expression levels are closely associ-
ated with the differentiation status in AML blasts. Interest-
ingly, a strong inverse correlation between the expression 
levels of Lyn and patients’ age was also observed, whereas 
no correlation was observed between its expression and the 
WBC numbers (Fig. 2e, f; Table 1). Therefore, our results 
suggest that the expression level of Lyn is closely linked to 
the differentiation status of AML blasts.
Our experimental data also showed that treatment 
with dasatinib alone clearly inhibited the expression of 
Table 1 Multiple clinical parameters of 31 AML patients and Lyn expression status of primary AML blasts
Primary AML blasts were obtained from 31 newly diagnosed AML patients with different FAB subtypes, except for FAB M3 (APL). The Lyn expression status of primary 
AML blasts from individual patients was analyzed by flow cytometer, and shown as mean fluorescence intensity (MFI). Multiple clinical parameters of individual 
patients were collected in Nihon University Itabashi Hospital
WBC white blood cells, MPO myeloperoxidase, NK normal karyotype, MDS/AML myelodysplastic syndrome overt acute myeloid leukemia, ND not detected
Patient 
number






1 45 M M4E inv (16) (p13;q22) 10,900 88 75.3
2 56 F M2 t (8;21) (q22;q22) 23,700 100 124.5
3 53 F M2 t (8;21) (q22;q22), -X 2800 100 112.1
4 35 M M2 t (8;21) (q22;q22), del(11) (p13), +15 59,300 ND 78.8
5 59 M M2 21 trisomy 78,200 100 53.9
6 69 F M1 NK 264,700 100 24.2
7 67 M M1 NK 168,800 100 29.1
8 34 M M0 NK 1500 2 76.9
9 43 M M4 NK 512,800 91 103.2
10 21 M M1 t (X;5) (q28;q31) 6900 90 71.9
11 60 M M2 NK 800 6.5 60.3
12 36 M M2 NK 5300 97 109.3
13 56 M M2 NK 1200 94 91.8
14 40 F M2 NK 69,100 99 92.9
15 34 M M1 NK 43,400 20 51.1
16 59 M M4 NK 99,200 39.5 45
17 69 F M2 NK 149,000 98.5 35.8
18 68 M MDS/AML add (11) (q23) 78,700 23.5 50.2
19 55 M M2 NK 49,400 90 38.8
20 51 F M5a t (9;11) (p22;q23), +8 1500 0 71
21 65 M M4 NK 96,400 ND 27.4
22 56 M M1 NK 25,300 17.2 19.1
23 61 M M2 Complex 140,300 92 92.8
24 46 M M2 Complex 60,600 31 40.2
25 56 M MDS/AML Complex 23,000 ND 73.8
26 43 F M1 Complex 50,600 100 63
27 81 F M0 t (9;22) (q34;q11), add(7) (p13), −22 95,300 1 21.1
28 52 M M0 Complex 22,300 1.5 47.2
29 64 M MDS/AML Complex 93,200 9.5 57.6
30 16 M M1 ND 403,300 93.5 79.7
31 61 M M1 ND 23,100 9 70.6
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phosphorylated Lyn in HL-60 cells (Fig.  3a), consistent 
with a previous report showing that Lyn is the predomi-
nant activated SFK in HL-60 cells [12]. We further dem-
onstrated that treatment with ATRA and VD3 resulted 
in differentiation induction in HL-60 cells as evidenced 
by the morphological changes and the increase in CD11b 
and/or CD11c expression levels (Fig.  3b–d). Although 
dasatinib per se did not clearly induced differentia-
tion of HL-60 cells, the differentiation-inducing activ-
ity of ATRA was prominently enhanced by the addition 
of dasatinib (Fig.  3b–d). In agreement with our results, 
Congleton et al. and Kropf et al. have also reported simi-
lar phenomena, although the concentrations of dasatinib 
used in respective study were somewhat different [12, 
14]. More important, we demonstrated that dasatinib 
also prominently enhanced the differentiation-inducing 
activity of VD3, which has been being studied as poten-
tial agent for differentiation therapy of AML. Since the 
concentrations of VD3 for in  vitro and animal experi-
ments far exceed those that can be tolerated by human 
beings [36, 37], it has not yet been translated to the clinic. 
To our knowledge, this is the first report regarding the 
combinatorial effect of VD3 and dasatinib in myeloid cell 
differentiation, and might provide fundamental insights 
for this combination therapy in patients with AML.
c-Myc is a transcription factor and its deregulation is 
common in leukemias and lymphomas in which over-
expression of c-Myc occurs generally [19, 26]. Previous 
reports have demonstrated that repression of c-Myc is 
required for terminal differentiation of malignant hemat-
opoietic cells including HL-60 induced by different stim-
ulants such as ATRA and VD3 [23–26]. In agreement 
with these previous reports, our results demonstrated 
that downregulation of the expression of c-Myc pro-
tein was induced by either ATRA or VD3 alone (Fig. 4), 
thereby reconfirming a vital role of c-Myc in ATRA/VD3-
induced HL-60 differentiation. Due to the critical role of 
c-Myc in differentiation and cell fate decision, it is tightly 
controlled through complex signaling pathways [19, 29]. 
It is noteworthy that two phosphorylation sites, threo-
nine 58 and serine 62 exist in the N-terminus of c-Myc 
[19]. Threonine 58 is targeted by glycogen synthase 
kinase (GSK-3β) whose phosphorylation is known to be 
responsible for destabilization of c-Myc [28]. Moreover, 
inhibition of Akt signaling pathway is associated with 
the activation of GSK-3β, resulting in the degradation of 
c-Myc through the ubiquitin–proteasome pathway [19, 
27]. On the other hand, serine 62 is a target of Erk whose 
phosphorylation is reported to stabilize c-Myc [19]. In 
the current study, along with the downregulation of 
c-Myc in the HL-60 cells treated with ATRA, VD3, each 
alone or in combination with dasatinib, downregulation 
of the phosphorylation of Akt and Erk was observed con-
comitantly (Fig. 5). Taking these previous results and our 
observations into account, we suggest that downregula-
tion of c-Myc implicated with the repression of the acti-
vation of Akt and Erk may contribute to the induction 
of HL-60 differentiation by these reagents. More impor-
tantly, in comparison with the treatment with ATRA or 
VD3 alone, dasatinib significantly strengthened their 
ability to downregulate the c-Myc expression, although 
dasatinib per se did not affect the phosphorylation of 
Akt and Erk, even if when combined with ATRA or VD3 
(Figs.  4, 5). It still remains uncertain and controversial 
with respect to the effects of dasatinib on the activation 
of Akt and Erk. A previous report has demonstrated that 
dasatinib downregulates the activation of Akt and Erk, 
contributing to its antitumor effects in nasopharyngeal 
Fig. 1 Representative flow cytometry histograms of Lyn expression 
and a positive correlation between the expression levels of total 
and phosphorylated Lyn in primary AML blast cells from patients. 
The expression levels of Lyn in primary AML cells were analyzed and 
presented as histograms plotted by flow cytometry as described 
in “Methods” section. a Histograms show the high (patients #9 and 
#25) and low (patients #7 and #21) Lyn expression level in respective 
primary AML blast cells of individual patients. b A strong correla-
tion between the expression levels of total and phosphorylated Lyn 
(p-Lyn). MFI mean fluorescence intensity
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carcinoma [38]. Furthermore, Chen et  al. has demon-
strated that dasatinib enhances cisplatin sensitivity in 
human esophageal squamous cell carcinoma cells via 
suppression of the activation of Akt [39]. On the other 
hand, similarly to our results, previous reports have dem-
onstrated that dasatinib did not cause detectable differ-
ences in Erk and Akt in HL-60 cells [14] and human AML 
progenitor cells [40], respectively. It is worth noting that 
signal transducer and activator of transcription 3 (Stat3) 
has been suggested to be involved in dasatinib-triggered 
inhibition of c-Myc expression [39], suggesting a possi-
bility of an implication of Stats3 for the downregulation 
of c-Myc expression. Overall, our results suggested that 
the mechanisms underlying downregulation of c-Myc 
by dasatinib clearly differ from that by ATRA/VD3. Col-
lectively, we suggested that Lyn has a critical role in the 
Fig. 2 Correlation between the expression level of Lyn and clinical laboratory parameters. The expression levels of Lyn in primary AML cells 
obtained from 31 patients with different subtypes of AML were analyzed with flow cytometry. Multiple clinical parameters of individual patients 
were collected in Nihon University Itabashi Hospital, and the assessment of the expression level of CD15 was entrusted to Bio Medical Laboratories, 
Inc. The correlation between the expression levels of Lyn and different cytogenetic risk groups (a), different AML subtypes (b), MPO activity (c), the 
expression level of CD15 (d), patients’ age (e) and WBC numbers (f) were shown respectively
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negative regulation of the induction of HL-60 differen-
tiation by either ATRA or VD3 through modulation of 
c-Myc expression, although the detailed mechanisms 
underlying the correlation are needed to clarify. Further 
investigation of the molecular details is ongoing.
Conclusions
We demonstrated a clear positive correlation between the 
expression levels of Lyn and differentiation status of pri-
mary AML blasts. We further demonstrated that dasatinib 
not only enhanced the differentiation-inducing activity of 
Fig. 4 Potentiation of ATRA- or VD3-induced c-Myc downregulation by dasatinib in HL-60 cells. After treatment with 1 μM ATRA, 100 nM VD3, alone 
or in combination with 300 nM dasatinib, for 72 h, the alteration of c-Myc expression in HL-60 cells was examined by intracytoplasmic staining 
using flow cytometry as described in “Methods” section. The relative expression level of c-Myc is shown as the mean fluorescence intensity (MFI). a 
Representative histogram rofiles are shown. b The relative expression level of c-Myc was calculated based on flow cytometry profiles shown in (a). 
Six independent experiments were carried out and results are shown as mean ± SD. *p < 0.05 vs. control; #p < 0.05 vs. ATRA; †p < 0.05 vs. VD3
(See figure on previous page.) 
Fig. 3 Inhibition of phosphorylation of Lyn and enhancement of differentiation-inducing activity of both ATRA and VD3 by dasatinib in HL-60 cells. 
a After treatment with 300 nM dasatinib for 30 min, the expression levels of phosphorylation of Lyn were evaluated by flow cytometry as described 
in “Methods” section. b–d After treatment with 1 μM ATRA or 100 nM VD3 in the presence or absence of 300 nM dasatinib for 72 h, morphological 
changes and the expression profiles of CD11b and CD11c were evaluated by Wright-Giemsa staining, and flow cytometry, respectively, as described 
in “Methods” section. b Representative photomicrographs are shown from three independent experiments. c Flow cytometry profiles of CD11b and 
CD11c. d Percent of CD11b and CD11c positive cells were calculated, respectively, based on flow cytometry profiles shown in (c). Experiments were 
independently repeated at least three times and results are shown as mean ± SD). p-Lyn dasatinib+, the expression level of phosphorylated Lyn in 
the presence of dasatinib; p-Lyn dasatinib−, the expression level of phosphorylated Lyn in the presence of dasatinib. *p < 0.05 vs. control; #p < 0.05 
vs. ATRA; †p < 0.05 vs. VD3
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ATRA but also that of VD3 in HL-60 cells, suggesting that 
Lyn was associated in the negative regulation of ATRA- 
or VD3-induced HL-60 cells differentiation. Our results 
also suggested that the enhanced differentiation-inducing 
activity probably was attributed to the downregulation of 
c-Myc implicated with the suppression of the activation of 
Akt and Erk in ATRA- or VD3-mediated HL-60 differen-
tiation. These findings thus provide novel insights into a 
possible combinational therapeutic approach by targeting 
Lyn for AML patients, and offer new possibilities for the 
combination therapy with VD3 and dasatinib.
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